Rockwell Med stock analysis
Want to see RMTI full AI Analyst Report?
Rockwell Med (RMTI) Stock Price & Analysis
RMTI Stock Chart & Stats
- Day’s Range
- $6.06 - $7.27
- 52-Week Range
- $4.89 - $12.90
- Previous Close
- $6.61
- Volume
- N/A
- Average Volume (3M)
- 27.25K
- Market Cap
- $26.64M
- Enterprise Value
- $24.91M
- Total Cash (Recent Filing)
- $22.54M
- Total Debt (Recent Filing)
- $13.53M
- Price to Earnings (P/E)
- ―
- Beta
- 0.60
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- -0.43
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Sales And Customer Expansion
Strong quarterly growth reflects both customer acquisition and deeper purchasing by major dialysis providers, supporting repeat demand for essential treatment products. Broader adoption across clinics can improve utilization of Rockwell’s portfolio and create a durable base for future revenue expansion.
Improved Balance-sheet Strength
Manageable leverage gives Rockwell greater financial flexibility than in 2021–2022, when leverage was extreme and equity was thin. A stronger capital base can help the company fund operations, pursue strategic initiatives, and absorb execution volatility without relying as heavily on additional borrowing.
Potential Global Platform Expansion
The proposed acquisition could materially broaden Rockwell from a more focused concentrates business into a global hemodialysis platform with recurring revenue characteristics. Added products, customers, manufacturing capacity, and distribution may improve scale and cross-selling if the transaction closes and integration is effective.
Bears Say
Persistent Unprofitability
Rockwell remains loss-making despite improvement from earlier periods, and its low gross margin leaves limited room to cover operating expenses. Continued negative returns on equity indicate that the business is not yet converting its capital base into sustainable earnings, weakening internal funding capacity.
Acquisition And Outlook Uncertainty
Withdrawing guidance makes near-term revenue, margin, and cash-flow planning less predictable while acquisition-related expenses continue. The pending closing also leaves the expected strategic scale unrealized for now, exposing results to transaction timing, approval, and execution uncertainty over coming quarters.
Cost Pressure And Declining Cash
Input and freight inflation directly reduced gross-margin performance, while the lower cash balance shows that working-capital needs and automation spending are consuming liquidity. Unless pricing, productivity, or supply-chain actions offset these pressures, they can delay the path to durable profitability.
Rockwell Med News
RMTI FAQ
What was Rockwell Med’s price range in the past 12 months?
What is Rockwell Med’s market cap?
When is Rockwell Med’s upcoming earnings report date?
How were Rockwell Med’s earnings last quarter?
Is Rockwell Med overvalued?
Does Rockwell Med pay dividends?
What is Rockwell Med’s EPS estimate?
How many shares outstanding does Rockwell Med have?
What happened to Rockwell Med’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Rockwell Med?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Rockwell Med
Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mark Strobeck
- Employees
- 157
- Website
- www.rockwellmed.com
- Address
- 30142 South Wixom road, Wixom, MI, 48393, US
Rockwell Med (RMTI) Earnings & Revenues
RMTI Earnings Call
Earnings Call SentimentPositive
The call was strongly optimistic about core hemodialysis sales growth, improved gross profit and margins, customer expansion, the potential scale of the pending Vantage acquisition, and the supportive direction of the HHS Kidney Care National Plan. However, the company reported operating losses, negative adjusted EBITDA, higher input and freight costs, a lower cash balance and withdrawal of full-year guidance. Overall, the positive operating momentum and strategic acquisition opportunity significantly outweighed the disclosed financial challenges.
View all RMTI earnings summariesRMTI Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 15 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |












